kabutan

Modalis Therapeutics Corporation(4883) Summary

4883
TSE Growth
Modalis Therapeutics Corporation
63
JPY
-1
(-1.56%)
Dec 5, 12:45 pm JST
0.40
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
63
Dec 5, 12:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.94
Yield
ー%
Margin Trading Ratio
5,129.87
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
63 JPY 0.40 USD
Previous Close Dec 4
64 JPY 0.41 USD
High Dec 5, 9:03 am
64 JPY 0.41 USD
Low Dec 5, 12:38 pm
62 JPY 0.39 USD
Volume
698,100
Trading Value
0.04B JPY 0.28M USD
VWAP
63.01 JPY 0.41 USD
Minimum Trading Value
6,300 JPY 40 USD
Market Cap
5.15B JPY 0.03B USD
Number of Trades
68
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
551
1-Year High Jun 9, 2025
9,562
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 11,050,000
Nov 21, 2025 0 11,394,700
Nov 14, 2025 0 11,933,000
Nov 7, 2025 0 11,704,000
Oct 31, 2025 0 11,860,100
Company Profile
Modalis Therapeutics Corporation conducts research and development of gene therapy drugs using its proprietary genome editing platform. The company has a base in the United States.
Sector
Pharmaceuticals
Modalis Therapeutics Corporation utilizes its proprietary genome editing platform, centered on CRISPR-GNDM technology, to research and develop gene therapy drugs. This technology functions as a "gene switch" that can control gene expression without cutting DNA, offering higher safety compared to conventional genome editing methods. The company aims to address genetic diseases, which are often in the rare disease category and inefficient to develop using traditional drug discovery approaches, by leveraging its technological prowess. Modalis employs a hybrid business model, combining partnerships with pharmaceutical companies ("collaboration model") and in-house development ("proprietary model"). The collaboration model aims for early revenue generation, while the proprietary model targets larger future revenues. The company has several ongoing development pipelines and aims to secure licensing agreements at specific stages of development.